Skip to main content

Table 2 Response to pre-emptive CMV therapy

From: Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation

  All (n = 61) Valacyclovir (n = 15) Valganciclovir (n = 16) Foscarnet (n = 30) P
Median time to antigenemia (days from transplant, range) 27 (12–387) 39 (16–387) 31.5 (15–119) 24.5 (12–104) 0.084
Median viral load (No. of CMV positive cells per million leukocytes, range) 3 (1–750) 3 (1–40) 3 (2–181) 3.5 (1–750) 0.772
Clearance, N (%) 60 (98.1) 15 (100) 16 (100) 29 (96.7) 0.591
Recurrent antigenemia, N (%) 34 (55.8) 7 (46.7) 11 (68.8) 16 (53.3) 0.434
Median days to recurrence 43.5 (11–173) 59 (27–173) 42 (14–94) 38 (11–163) 0.081
  1. CMV, cytomegalovirus